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Abstract 
We summarize the major points of international debate on health risk studies for the main 
commercialized edible GMOs. These GMOs a r e   s o y ,   m a i z e   a n d   o i l s e e d   r a p e   d e s i g n e d   t o  
contain new pesticide residues since they have been modified to be herbicide-tolerant (mostly 
to Roundup) or to produce mutated Bt toxins. The debated alimentary chronic risks may 
come from unpredictable insertional mutagenesis effects, metabolic effects, or from the new 
pesticide residues. The most detailed regulatory tests on the GMOs are three-month long 
f e e d i n g   t r i a l s   o f   l a b o r a t o r y   r a t s ,   w h i c h   a r e   b i o c h e m i c a l l y   a s s e s s e d .   T h e   t e s t s   a r e   n o t   c o m-
pulsory, and are not independently conducted. The test data and the corresponding results 
are kept in secret by the companies. Our previous analys e s   o f   r e g u l a t o r y   r a w   d a t a   a t   t h e s e  
levels, taking the representative examples of three GM maize NK 603, MON 810, and MON 
863 led us to conclude that hepatorenal toxicities were possible, and that longer testing was 
necessary. O u r   s t u d y  w a s   c r i t i c i z e d   b y   t he company developing the GMOs in question and the 
regulatory bodies, mainly on the divergent biological interpretations of statistically significant 
biochemical and physiological effects. We present the scientific reasons for the crucially dif-
ferent biological  interpretations and also  highlight  the  shortcomings in the experimental 
protocols designed by the company. The debate implies an enormous responsibility towards 
public health and is essential due to nonexistent traceability or epidemiological studies in the 
GMO-producing countries. 
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Introduction and Context 
The debate on the safety of genetically modified 
o r g a n i s m s   ( G M O s )   u s e d   f o r   f o o d   a n d   f e e d   i s   s t i l l   v e r y  
l i v e l y   t h r o u g h o u t   t h e   w o r l d ,   m o r e   t h an 15 years after 
their first commercial release [3-5].   H u g e   s o c i a l ,   e c o-
nomical, and political issues have been raised. Un-
fortunately, although some stakeholders claim that a 
h i s t o r y   o f   s a f e   u s e   o f   G M O s   c a n   b e   u p h e l d ,   t h e r e   a r e  
n o   h u m a n   o r   a n i m a l   e p i d e m i o l o g i c a l   s t u d i e s   t o   s u p-
p o r t   s u c h   a   c l a i m   a s   y e t ,   i n   p a r t i c u l a r   b e c a u s e   o f   t h e  
lack of labeling and traceability in GMO-producing 
c o u n t r i e s .   A s   a   m a t t e r   o f   f a c t ,   9 7 %   o f   e d i b l e   G M O s  
among cultivated GMOs (soy, corn and oilseed rape 
or canola, excluding cotton) a r e   g r o w n   i n   S o u t h   a n d  
North America [6],   w h e r e   G M O s   a r e   n o t   l a b e l e d .   A l l  
these plants have been modified to tolerate and/or 
produce  one  or  more  pesticides  [6],  and  contain 
therefore such residues at various levels [5]. Most are 
Roundup  residues  (it  is  a  major  herbicide  used 
w o r l d w i d e   a n d   t o l e r a t e d   b y   a b o u t   8 0 %   o f   G M O s ) .  
Other residues are from modified Bt insecticide tox-Int. J. Biol. Sci. 2010, 6 
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i n s ,   w h i c h   a r e   d i r e c t l y   s y n t h e s i z e d   b y   t h e   G M   p l a n t s  
from transgenes.  
T h e   d e b a t e   o n   h e a l t h   r i s k s   i s   f i r s t   o f   a l l   b a s e d   o n  
theoretical considerations, and second on the know-
ledge derived from mammalian experiments fed on 
GMOs. The latter experiments are not systematically 
p e r f o r m e d ,   a n d   c a n   b e   p a r t   o f   n o n -compulsory regu-
latory  tests.  The  scientific  question  about  edible 
GMOs health risks amo u n t s   t o   h o w   t h e y   h a v e   b e e n  
tested and interpreted, especially in mammals. Nutri-
t i o n a l   t e s t s   w i t h   w e i g h t ,   b o n e   m a s s ,   a n d   f o r   i n s t a n c e  
milk or meat production are available, as well as acute 
toxicological tests with recombinant proteins, in vitro 
digestibility of transgenic proteins, and limited com-
positional analysis among other data. However, the 
possible chronic side effects of pesticide residues are 
not  scientifically  assessed,  whereas  these  edible 
GMOs  were  modified  in  order  to  either  tolerate  or 
produce   s u c h   r e s i d u e s   i n   t h e   f i r s t   p l a c e .   I n   a d d i t i o n ,  
unpredictable  metabolic  effects,   s u c h   a s   m e t a b o l i c  
interferences,   o r   d i r e c t   o r   i n d i r e c t   i n s e r t i o n a l   m u t a-
genesis consequences cannot be excluded. All these 
possibilities have been summarized (Fig. 1). For  in-
stance, insertion of the transgene in varieties produc-
ing  Cry1Ab  toxin  caused  a  complex  recombination 
e v e n t ,   l e a d i n g   t o   t h e   s y n t h e s i s   o f   n e w   R N A   p r o d u c t s  
encoding unknown proteins [7], or/and to metabolic 
pathways variations which caused up to 50% changes 
in measured osmolytes and branched aminoacids [8]. 
T h e   f r e q u e n c y   o f   s u c h   e v e n t s   i n   c o m p a r i s o n   t o   c l a s-
sical  hybridization  is  by  nature  unpredictable  and 
n e w   p r o t e o m i c   t e c h n o l o g i e s   h a v e   s h o w n   t o   b e   effec-
tive in evaluating the potential collateral effects due to 
insertional mutagenesis [9]. 
In   o r d e r   t o   a n a l y z e   s u b c h r o n i c   o r   c h r o n i c   t o x-
icological  signs,  it  is  more  informative  to  focus  on 
studies including numerous blood and organ para-
meters. Most of these are 90 day-long feeding regula-
tory trials on rats eating GM corn or soy. The raw data 
i s s u e d   b y   t h e   c o m p a n i e s   p a r t i c u l a r l y   a t t r a c t e d   o u r  
interest. We obtained the said data by Court order and 
lawyers (since the data were previously kept secret). 
We recently published a second batch of new assess-
ments [1, 2, 5]. We reviewed all of them, and they re-
vealed significant statistical differences (~9%) which 
concentrate  mostly  on  kidneys  and  livers,  and  are 
c o n s i d e r e d   b o t h   b y   t h e   c o m p a n i e s   a n d   t h e   o f f i c i a l  
approval committees as irrelevant where the safety of 
GMOs is concerned [10].  
 I n   f a c t ,   b e h i n d   t h i s   s c i e n t i f i c   c o n t r o v e r s y ,   w h a t   i s  
a t   s t a k e   r e a l l y   i s   t h e   c o m m e r c i a l i z a t i o n   ( o r   n o t )   o f  
GMOs  ar o u n d   t h e   w o r l d ,   a n d   o v e r a l l ,   t h e   r u l e s   o f  
scientific  assessment  that  could  be  modified.  The 
present  rules  for  GMO  risk  assessment   a r e   m a i n l y  
based on the concept of substantial equivalence that 
w a s   a c c e p t e d   b y   O E C D   i n   1 9 9 3   a n d   t h e n   i n c l u d e d   i n  
t h e   F D A   ( F o o d   a n d   D r u g   A d m i n i s t r a t i o n )   r e g u l a t i o n  
( P a r t   I X   :   F o o d s   D e r i v e d   F r o m   N e w   P l a n t s   V a r i e t i e s )   :  
« In most cases the substances expected to become compo-
nents of food as a result of genetic modification will be the 
same as or substantially similar to substances commonly 
found in food such as proteins, fats and oils, and carbohy-
drates. » S u c h   a   c o n c e p t   i s   s u b j e c t e d   t o   debate in the 
scientific community because it is based on a simplis-
tic view of living cells. In particular, it overlooks all 
the interactions between genes, and the direct or in-
direct potential metabolic consequences of insertional 
mutagenesis.  This  implies  that  GMOs  are  insuffi-
ciently evaluated. We realize that the requirement for 
longer and more detailed regulatory tests would re-
d u c e   t h e   p r o f i t a b i l i t y   o f   G M O s ,   b u t   p r o t e c t i n g   m a m-
malian and human health seems even more essential 
in our views.  
Some  official  agencies  authorizing GMOs con-
s u m p t i o n   e v e n t u a l l y   d e c i d e d   n o t   t o   t a k e   i n t o   a c c o u n t  
our  published  results  [1,  2],  and  in  particular  the 
agencies  defended  Monsanto’s  opinions  on  their 
websites.  Here,  we  review  the  arguments  of  the 
scientific debate for data interpretation: 
 I t   i s   w e l l   k n o w n   t h a t   t h e r e   w ere different opi-
nions over  the  interpretations  of  the  significant  dif-
f e r e n c e s   i n   t h e   b l o o d   a n d   o r g a n s   o f   r a t s   e a t i n g   G M O s  
in  comparison  to  controls,  especially  in  our  coun-
ter-analyses  on  the  raw  data  of  three  toxicological 
tests carried out by Monsanto, the results of which we 
obtained by Court decision [1, 2]. These tests pertain 
t o   t h r e e   G M   c o r n s   o w n e d   b y   M o n s a n t o :   M O N   8 6 3   a n d  
M O N   8 1 0   w h i c h   a r e   c o n t i n u o u s l y   p r o d u c i n g   a   r o ot-
worm and a corn-borer insecticide, respectively, and 
NK  603  Roundup-tolerant  maize,  which  contains 
Roundup herbicide residues. Although the European 
legislation requests transparency of health and envi-
ronmental  impacts  in  regulatory  tests,   t h e   r a w   d a t a  
were first considered as confidential by biotech firms. 
I t   i s   a l s o   t r u e   f o r   a l l   o t h e r   c o m m e r c i a l i z e d   G M O s ,   e s-
p e c i a l l y   t h o s e   v a r i e t i e s   p r o d u c i n g   o r   t o l e r a t i n g   o n e   o r  
s e v e r a l   p e s t i c i d e s ,   f o r   w h i c h   t h e   d a t a   s h o u l d   b e   m a d e  
public. 
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F i g   1 .   P r o p o s e d   m o d e   o f   a c t i o n s of agricultural GMOs and/or associated pesticides on health. Almost all 
GMOs disseminated in the environment are plants, namely soy, maize, cotton, and oilseed rape (1995-2010). Their genetic 
and phenotypic modifications are only herbicide tolerance and / or insecticide production (modified Bt toxins) in more than 
99% cases. Thus they can be described as pesticide plants. Consequently, two major health risks are described: (1) due to 
mid or l o n g   t e r m   s i d e   e f f e c t s ,   b r o u g h t   b y   n e w   p e s t i c i d e   r e s i d u e s   i n   f o o d   o r   f e e d ,   a n d   d i r e c t l y   d u e   t o   t h e   n e w   g e n e t i c  
characteristic. These residues can be from herbicide(s) absorbed by tolerance (Roundup residues in more than 90% her-
bicide-tolerant GMOs) in most cases, or from new modified insecticide Bt toxins, mutated or truncated in all insecti-
cide-GMOs. (2) Insertional mutagenesis linked to the genetic modification, or post-genomic metabolic interferences or 
derivations. These are direct or indirect less specific effects independent from the toxicology assessment of the transgene 
product. These unexpected possible consequences cannot be approached by gross substantial equivalence studies without 
metabolomic analyses. They can be invisible on the plant phenotype, but still able to induce long term toxicity after con-
sumption, specific to each genetic transformation. The possible combined effects between all these impacts cannot be 
excluded, inducing chronic pathologies after regular consumption. Only long term testing (more than 3 months in mammals) 
could answer these possibilities. Thus, regulatory agencies must adapt their methods for health risk assessments of agri-
cultural GMOs, taking into account associated pesticides and their formulations. They should also approach combined 
e f f e c t s   a t   d i f f e r e n t   p e r i o d s   o f   l i f e   a n d   o n   s e v e r a l   g e n e r a t i o n s ,   t o   b e   c o m p l e t e ,   o v e r a l l   w h e n   a   n e w   f o o d / f e e d   c o n c e r n s   b i l l i o ns 
of people without traditional knowledge of its consumption. 
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Debate on the shortcomings of the experi-
mental design  
All  regulatory  90-d a y   r a t   f e e d i n g   s t u d i e s   w i t h  
GMOs  have  been  constructed  on  the  same  scheme. 
The shortcomings of the experimental design are un-
derlined below and summarized (Table 1): 
a) Too small number of animals were studied: 10 
individuals were measured for biochemical parame-
t e r s   o u t   o f   2 0   p e r   g r o u p .   T h i s   m i g h t   b e   e n o u g h   f o r  
long-t e r m   e x p e r i m e n t s ,   b u t   n o t   o v e r   s u c h   a   s h o r t   p e-
r i o d   o f   t i m e ,   a s   n a t u r a l l y   a   s m a l l   n u m b e r   o f   e f f e c t s   o r  
only  effects  of  low  amplitude  were   i n d u c e d ,   t o   b e  
compared to a slowly developing chronic pathology. 
This kind of protocol could result in low power sta-
tistical  tests  and  therefore  too  many  false  negative 
results (for example, it could be misleading, and in-
duce by mistake the research worker to reject a possi-
ble effect of the consumption of GMOs).  
b )   T o o   m a n y   c o n t r o l   r a t s :   t he number of controls 
i s   f o u r   t i m e s   h i g h e r   i n   t h e   r e g u l a t o r y   t e s t s   that have 
b e e n   u s e d   a l l   o v e r   t h e   w o r l d   t o   a u t h o r i z e   t h e   m a i n  
GMOs.  Such  an  imbalance  between  control  and 
treated rats may conceal the visible effects. Out of 400 
rats, there were only 80 eating GMOs (and only 40 
biochemically analyzed), thus 4 groups of 10 animals, 
w i t h   2   d o s a g e s   ( 1 1   a n d   3 3 %   G M O   i n   e q u i l i b r a t e d  
d i e t ) ,   a n d   2   b l o o d   a n a l y s e s   p e r   g r o u p   ( a f t e r 5 and 14 
weeks).  Both  sexes  were  equally  represented.  But 
overall we judge the 320 “reference animals” too nu-
m e r o u s   i n   c o m p a r i s o n   t o   t h e   t r e a t e d   o n e s .   A s   o n l y  
h a l f   o f   t h e   r a t s   w e r e   s t u d i e d   o n   a l l   t h e   b i o c h e m i c a l  
a n d   b l o o d   p a r a m e t e r s ,   t h i s   m e a n s   t h a t   t h e   decisions 
w e r e   m a d e   o n l y   o n   4 0   r a t s   e a t i n g   G M O s   a n d   a s s e s s e d  
from a group of 400 animals, over 90 days. 
c )   T o o   m a n y   c o n t r o l   t r e a t m e n t s :   t h e   3 2 0   n o n -GM 
fed animals were treated in fact with 7 different diets 
which were supposed to represent a variability of the 
possible  regimen.  Six  constituted  the  so-called “ref-
e r e n c e ”   g r o u p s   w i t h   f e e d   n o t   d e m o n s t r a t e d   a s   s u b-
stantially equivalent. Moreover, only two dosages in 
the control groups were chemically equivalent to the 
GM diets that were made with the isogenic maize or a 
c o r n   c l o s e   t o   t h e   G M   v a r i e t y . But two doses are insuf-
ficient to study any dose-related effect. 
 d) The rat was the only mammal fed with GMOs 
for 3 months.   
 e )   T h e   r e g u l a t o r y   t e s t   w a s   o n l y   p e r f o r m e d   o n c e  
f o r   e a c h   G M O ,   w h i c h   w a s   t h e n   s u p p o s e d   t o   b e   eaten 
all over the world.   
 f )   T h e   d u r a t i o n   o f   9 0   d a y s   i s   t h e   l o n g e s t   t e s t   on 
f i l e   a n d   o n l y   o n   y o u n g   a d u l t   m a m m a l s ;   i t   w a s   n o t  
long enough to observe chronic effects.   
 g) The lack of developmental, reproductive as 
well as chronic or multi-generational tests is the sub-
j e c t   o f   a   h e a t e d   d e b a t e   f o r   t h e   G M O s   c u r r e n t l y   a v a i l-
able on the market. 
 This experimental protocol from Monsanto was 
accepted  by  several  official  committees,  first  confi-
dentially. This procedure is a point of controversy not 
only with Monsanto, but also with the agencies that 
have published opinions on our work [1, 2, 5]. We will 
refer to their opinions collectively as Monsanto et al. 
in the following,   u n l e s s   o t h e r w i s e   s p e c i f i e d ,   t o   s i m p l-
ify the reading of this paper. 
 
T a b l e   1 . Insufficiencies of currently used tests, criteria and interpretations; proposed improvements for GMOs health risks 
assessment. We reviewed here the current protocols used by industry and regulatory committees in commercialized 
a g r i c u l t u r a l   G M O s .   T h e   f e e d i n g   t r i a l s   d e s c r i b e d   i n   c o l u m n   1   w e r e   p e r f o r m e d   i n   o r d e r   t o   o b t a i n   G M O s   c o m m e r c i a l i z a t i o n ,  
via regulatory agencies. The improvements proposed (column 2) will adapt these tests to modern knowledge in toxicology, 
in order to avoid the main consequences of overlooked risks (column 3). 
Critical parameters 
and interpretations 
Present regulatory assessment  Improvements proposed  Main consequences 
if improvements not applied 
Number of animals / group  10 measured on 20 /group  At least 20 rats for 3 months, 10 or 
more for 24 months / group 
Low statistical power 
Number of controls versus 
treatments 
Too many reference or control 
groups (320)/ 80 GMO-treated only 
Avoid to multiply completely dif-
ferent control groups 
Risk of concealing statistical 
effects 
Species  Rat only (in mammals with blood 
analyses) 
Rat and other(s) species such as Mice 
/ Rabbit 
Results too much species-specific 
Replication of toxicological 
test 
Only once  At least two  Reproducibility, Reliability not 
proven 
Length  Subchronic (3 months)  Chronic (24 months) + develop-
mental  + transgenerational 
Missing long term, fetal or 
transgenerational effects 
Doses  2 doses  3 doses  Missing dose response relation-
ship 
Type of treatment  GMO  GMOs with/without associated 
pesticides 
Confusion between mutagenesis 
/ pesticides effects 
Food composition  Substantial equivalence  More detailed composition with 
specific pesticides residues and me-
tabolites, adjuvants 
Missing potential contaminants 
and combined effects Int. J. Biol. Sci. 2010, 6 
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Norms followed  OECD 408 
strictly or less 
OECD 408-453 
with other details 
Lack of hormonal sex specific 
data for instance 
Number of blood analyses  2 measures only 
after 5 and 14 weeks 
At least 3 the first trimester  Missing punctual phenomena 
Biological interpretations 
Dose-effects 
“Dose-related”: 
proportional effects only taken into 
account with two doses ! 
Non linear effects to be studied (U or 
J curves) 
Risk to avoid endocrine, carci-
nogenic, immune long-term ef-
fects… 
Biological interpretations 
Sex specificity 
Effects  studied only if occurring in 
both sexes 
Sex specific effects to be studied  Risk to avoid endocrine-specific 
effects 
Biochemical modifications 
linked to histopathology 
Necessary  Not always possible in 3 months  Risk of false negative results 
Amplitude of effects studied  Effects inside of undefined historical 
norm of the species not studied 
Any statistical difference with con-
trols to be studied 
Risk of false negative results 
Final biological conclusion 
for an effect 
Should be plausible for the regula-
tory committee 
Necessity of more objective criteria: 
ex. lengthening of the test 
Major risk of subjective interpre-
tation 
 
 
Debate on statistical tests 
I f   f a l s e   p o s i t i v e   e f f e c t s   a r e   t h e   c o n c e r n   o f   M o n-
santo et al .   a s   w e l l   a s   o f   S é r a l i n i   e t   a l .   [1, 5], we have 
underlined  that  false  negative  effects  may  be  also 
amplified by the poor experimental design that curbs 
enough  statistical  power.  Moreover,  the  fact  that 
E F S A   a n d   H C B   a s k e d   f o r   a   r e v i s i o n   o f   s t a t i s t i c a l   m e-
thods  [13-14],  implies  that  the  accepted  regulatory 
tests are insufficient for the time being, at least at this 
level. Therefore, as such, the  experimental  protocols 
admitted by Monsanto et al., even if advocated by the 
O E C D ,   d o   n o t   a p p e a r   c a p a b l e   o f   offering  statistical 
p r o o f s   o f   h e a l t h   r i s k s   n o r   o f   t h e i r   a b s e n c e   e x c e p t   f o r  
highly  noticeable  health  risks.  Monsanto’s  tests 
should have been rejected by the international com-
mittees, if this argument fits. Only early warnings of 
toxicity  can  be  suggested  now, as already indicated 
[2]. 
 M o r e o v e r ,   i t   h a s   t o   b e   n o t i c e d   t h a t   S é r a l i n i   e t   a l .  
[1] and Spiroux de Vendômois et al. [2] d i d   n o t   t r y   t o  
test  mathematically, as a  whole,  whether  there  had 
been a “GMO effect” on all the parameters: dosage, 
duration  and  sex.  It  was  rather  established  by  sex, 
d u r a t i o n   a n d   d o s a g e ,   a   l i s t   o f   a l l   t h e   p a r a m e t e r s   dif-
ferentially  expressed  between  control  groups,  and 
g r o u p s   f e d   w i t h   G M O s .  Note  that  Monsanto  (raw 
data of MON 810, MON 863 and NK 603) do not cal-
culate more, and even le s s ,   s i n c e   t h e   1 1 %   d o s a g e   i s   n o t  
c o n s i d e r e d ,   i f   t h e   h i g h e s t   d o s e   o f   3 3 %   i s   n o t   d i f f e r e n t .  
Contrary to what Monsanto claims, the number and 
the nature of the signs we emphasize are not really 
different from the ones used in their reports. Howev-
e r ,   o u r   r e v e a l e d   s i g n s   a r e   c l a s s i f i e d   b y   o r g a n s   a n d   t a k e  
i n t o   a c c o u n t   t h e   d i f f e r e n t i a l   e f f e c t   r e l a t e d   t o   d o s a g e  
and sex. The difference between Monsanto’s conclu-
sions and ours is, again, about the biological inter-
pretation rather than mere statistical points. 
However, statistics can be discussed. The use of 
the ANOVA by Monsanto should not exempt them 
from doing an assessment of the power of the tests. At 
n o   t i m e   i n   t h e   c o m p a n y   s t u d i e s   t h i s   a s p e c t   w a s   h i g-
hlighted, although it is essential. As soon as a statis-
tic a l   t e s t   i s   u s e d   ( a   S t u d e n t   t   t e s t   a s   w e l l   a s   a n  
A N O V A ) ,   t h e   r e s u l t   i n t e r p r e t a t i o n   c a n   o n l y   b e   b a s e d  
on the one on the p-value that allows an estimation of 
the risk α of a Type I error when the null hypothesis is 
r e j e c t e d ,   a n d   o n   t h e   o t h e r   h a n d   o n   t h e   s t a t istical 
power 1-β   t h a t   a l l o w s   a n   e s t i m a t i o n   o f   t h e   r i s k   β   o f   a  
Type II error, when the null hypothesis is accepted. 
T h i s   p o w e r   a l l o w s   t h e   e s t i m a t i o n   o f   t h e   e f f e c t   s i z e .   I t  
is  not  because  a  hypothesis  is  not  rejected  that  it  is 
inevitably true. 
We know that t h i s   t e s t   p o w e r   d e p e n d s   o n   t h e  
s a m p l e   s i z e ,   o n   t h e   T y p e   I   r i s k   α,   a n d   o n   t h e   e f f e c t   s i z e  
w e   w a n t   t o   p i c k   u p .   I n   S p i r o u x   d e   V e n d ô m o i s   e t   a l .  
[2],   t h e   o n l y   e x a m p l e   o f   t h e   p o w e r   c a l c u l u s   i n   a   S t u-
d e n t   t e s t   i s   j u s t   a n   i l l u s t r a t i o n   a n d   n o t   a   d e m o n s t r a-
tion of the   f a c t   t h a t   M o n s a n t o ’ s   p o w e r   t e s t s   a r e   w e a k ,  
e v e n   i f   t h e y   a r e   t r u e .   T h e   s t a t i s t i c a l   p o w e r   i s   n ever 
calculated for any of their ANOVA.  
 As  a  matter  of  fact,  in  their  regulatory  reports 
Monsanto  et  al.  use  an  ANOVA  without  statistical 
p o w e r   f o r   e a c h   p a r a m e t e r ,   b o t h   f o r   e a c h   s e x   a n d   d u-
r a t i o n   ( w e e k   5   a n d   1 4 ) .   E v e n   i f   t h e r e   a r e   A N O V A  
calculations,  they  lead  to  the  implementation  of  a 
large number of statistical tests: 4 times the number of 
p a r a m e t e r s   ( 4   =   2   s e x e s   x   2   d u r a t i o n s ) .   A l s o   i n   t h i s  
c a s e   o f   m u l t i p l e   c o m p a r i s o n s ,   t h e   s t u d y   o f   t h e   f a l s e  
positives is not specific to the Student t test, and is not 
treated in these Monsanto’s studies. 
 Our goal while reviewing Monsanto's data [1, 2] 
w a s   t o   m a k e   a   l i s t   o f   a l l   t h e   d i f f e r e n t i a l l y   e x p r e s s e d  
parameters. Thus it was essential to suggest a study of 
t h e   f a l s e   p o s i t i v e s .   T h e   F D R   m e t h o d ,   a c c e p t e d   w i t h  
Benjamini-Yekutieli’s correction, makes it possible to 
take into account the potential dependency between 
the  parameters.  Also,  we  disagree  the  argument 
which claims that w h a t   i s   p i c k e d   u p   b y   t h i s   m e t h o d  
(but still statistically different) is inevitably obtained 
“by chance” (developed by some experts or agencies, Int. J. Biol. Sci. 2010, 6 
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Le Monde, 10/02/2010). The outcome still needs to be 
interpreted biologically. 
 T h e   n o r m a l   u s e   c o n d i t i o n s   o f   t h e Student t tests 
are not always satisfied: small samples (equal or fewer 
than 10) in subchronic tests, normality’s rejection by 
the Shapiro test and non homogeneity of variances. 
Thus we did apply nonparametric methods. But, even 
if Monsanto do make it clear (in all the “materials and 
methods” section of their reports of the raw data) that 
t h e y   d o   t h e   s a m e ,   t h e r e   i s   n o t   a n y   a p p l i c a t i o n   o f   i t   i n  
their  statistical  test  data:  for  each  parameter,  each 
d u r a t i o n ,   e a c h   s e x ,   o n l y   t h e   A N O V A   i s   i n d i c a t e d ,  
even when t h e   d a t a   n o r m a l i t y   o r   t h e   v a r i a n c e   h o m o-
g e n e i t y   i s   n o t   s a t i s f i e d .   A n d   y e t ,   t h e   p h y s i o l o g i c a l  
i n t e r p r e t a t i o n   i s   s u p p o s e d   t o   b e   b a s e d   o n   t h e s e   r e-
sults. 
Consensus on statistical effects 
 Not only does Monsanto admit major statistical 
differences for some parameters, but most of our re-
sults demonstrate huge discrepancies [2]. Significant 
and  non-significant  effects  correspond  to  Monsanto 
data (94-9 6 %   o f   t h e   t o t a l ,   d e p e n d i n g   o n   t h e   G M O ,  
deduced from Table E p 723 [2]). In the comment of 
our  study,  EFSA  [15] admits the presence of visible 
statistical effects in the results « The significant differ-
ences highlighted by Spiroux de Vendômois et al. have all 
been considered previously by the GMO panel... ». Ergo, 
the major scientific disagreements are only about the 
biological interpretations of the statistical effects.  
 There  remains  a  discussion  about  the  weight 
c u r v e s   f o r   M O N   8 6 3   t r e a t e d   r a t s   w h i c h   w e   h a v e   p u b-
lished [1],   b u t   t h a t   w e r e   n o t   i n   t h e   o r i g i n a l   r e p ort of 
Monsanto. The French committee CGB criticized the 
failure to take into account the individual variability 
f o r   e a c h   r a t   i n   o u r   f i r s t   p a p e r   [1]. However, even when 
taking that into account, they admitted a significant 
effect  on  the  female  weights'  variations  of  the 
GMO-f e d   g r o u p   i n   t h e i r   r e p o r t   o n   o u r   w o r k ,   w h i c h  
w a s   u s e d   b y   E F S A ,   b u t   s t i l l   d i s r e g a r d e d   i n   E F S A ' s  
opinion. The authorities should then have reacted to 
such a serious sign. We certainly consider this as a 
shortcoming.  
Divergent biological interpretations  
 Therefore, the biological interpretations become 
crucial after a global statistical consensus. Two possi-
ble issues here: either a demonstration of innocuous-
ness  (Monsanto  et  al.’s  opinion),  or  disturbing  dis-
ruptions that should be followed b y   l o n g e r   t e s t s   b e-
fore approvals (in our opinion). 
There are at least two arguments used by EFSA 
[15] and Monsanto et al. in general, to reject our study 
[2].   F i r s t ,   t h e y   s a i d   t h a t   o u r   d a t a   w e r e   o n l y   p r e s e n t e d  
in  percentages  and  not  in  absolute  values.  On  the 
contrary, we indeed published absolute values to give 
a n   i d e a   o f   t h e   c r u d e   e f f e c t s   f o r   M O N   8 1 0 ,   N K   6 0 3   [ [2], 
pp 724-5] and MON 863 [[1], p 600]. However, it does 
not change the results in any way. Secondly, the pa-
rameter  values  in  our  studies  are  compared  to  the 
controls  and  references  (boxes  and  double  boxes  in 
t h e   t a b l e s ) ,   c o n t r a r y   t o   w h a t   w a s   c l a i m e d   i n   E F S A ' s  
official opinion.  
 In  addition,  biological  interpretations  strongly 
diverge between us and Monsanto et al., on several 
key-points.  We  have  previously developed this de-
bate, at least in part, in two reviews [5, 10],   a n d   s u g-
gested improvements in regulatory tests: relative to 
transparency, length, with a duration corresponding 
to the lifespan of animals (2 years for the rat in labor-
atory for instance, as is done for some pesticides and 
d r u g s ) .   I t   h a s   b e c o m e   e s s e n t i a l   t o   o r g a n i z e   coun-
ter-evaluation.  
 EFSA  and  other  national  official  committees 
have accepted to recommend the commercial release 
a n d   c o n s u m p t i o n   o f   t h e s e   G M O s ,   b a s e d   o n   M o n s a n-
to's own tests and interpretation. The main differences 
between  their  biological  conclusions  and  ours,  fol-
lowing statistical differences in biochemical and organ 
parameters, are listed below: 
 a )   F o r   t h e   r e c o r d ,   w e   w o u l d   l i k e   t o   s t a t e   t h a t   b e-
sides  the  controversy  o n   t h e   s h o r t c o m i n g s   o f   t h e  
protocol design outl i n e d   a b o v e ,   a n y   e a r l y   s i g n   o f   d i f-
f e r e n c e   s h o u l d   b e   c o l l e c t e d   i n   a   t a b l e   t o   g e t   a   g l o b a l  
p i c t u r e   o f   t h e   a n i m a l   p h y s i o l o g y   a f t e r   G M O   c o n-
sumption. It is really impossible within 90 days, with 
a  single  experiment  worldwide  and  such  a  small 
n u m b e r   o f   r a t s ,   t o   g e t   a   c o n s i s t e n t   t o x i c o l o g i c a l   p i c-
t u r e ,   a s   r e q u e s t e d   b y   M o n s a n t o   e t   a l . ,   a n d   t o   c o n s i d e r  
t h e   d i s t u r b i n g   s i g n s   t h e y   i n d i c a t e .   T h i s   i s   a   m a j o r  
point, because we are concerned by possible chronic 
pathologies. 
Some effects may not be of major amplitude as 
yet; however, some are. For instance, the increase of 
the hearts' weight by 11% in males for NK603, or 40% 
increase in plasmatic triglycerides in females eating 
MON 863 (together with a pre-diabetic profile), could 
b e   c o n s i d e r e d   a s   e n o u g h   t o   t r i g g e r   a   m o r a t o r i u m .   A s   a  
matter of fact, Monsanto did not repeat their studies 
o r   m a d e   t h e m   t a k e   p l a c e   o v e r   a   l o n g e r   p e r i o d   o f   t i m e .  
They even routinely prevent independent reproduci-
b i l i t y   b y   r e f u s i n g   t o   s u p p l y   t h e   m a t e r i a l   n e eded  [12] 
a n d   b y   b l o c k i n g   a c c e s s   t o   c o n f i d e n t i a l   d a t a ,   a s   t h e y  
did by bringing the case before the Court of Appeal in 
Germany [1] (however, they lost the case).  
b) The statistical differences are often considered 
b y   M o n s a n t o   e t   a l .   b e t w e e n   t h e   G M -treated  groups 
and the so-called “historical standards of the species” Int. J. Biol. Sci. 2010, 6 
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which are undefined, as the also undefined “normal 
r a n g e ” .   T h i s   a p p r o a c h   m a k e s   i t   p o s s i b l e   f o r   t h e m   t o  
consider  larger  variations  as  normal,  for  subjective 
reasons. The differences have to be considered  first 
w i t h   t h e   c l o s e s t   c o n t r o l   g r o u p .   I t   i s   o n l y   a f t e r w a r d s  
t h a t   i t   m i g h t   b e   p o s s i b l e   t o   c o m p a r e   i t   w i t h   e x p e r i-
mental  reference  groups  (Monsanto  et  al.  did  that 
first) receiving a non-equivalent regimen (for instance 
w h e r e   s a l t s   o r   s u g a r s   a r e   c o n cerned). For the record, 
we  wish  to  underline  that  the  reference  groups  are 
still too numerous in comparison to the treated rats. 
 c) The significant effects are taken into account 
b y   M o n s a n t o   e t   a l .   o n l y   w h e n   t h e y   a r e   s i m i l a r   i n   b o t h  
sexes.  This  is  not  acceptable,  since  by  the  current 
knowledge [5] chronic pathologies, as well as the en-
docrine  disturbances  or  some  cancers,  are  usually 
sex-related  and  not  proportional  to  the  carcinogen 
d o s e   t a k e n   o v e r   a   s h o r t   p e r i o d   o f   t i m e .   T h e   d a t a   s p e-
cificity of the parameters changing and depending on 
s e x   h a s   j u s t   b e e n   a d m i t t e d   i n   M o n s a n t o ’ s   a n s w e r   t o  
our study ([16], p. 12).   
 d )   F o r   M o n s a n t o   e t   a l . ,   t h e   a b s e n c e   o f  
dose-dependent  effects  is  a  reason  to  overlook  the 
significant  differences.  This  is  also  unacceptable, 
simply because, for instance, the potential endocrine 
disrupting antagonistic actions need to be taken into 
account [17].   M o r e o v e r ,   i t   h a s   t o   b e   u n d e r l i n e d   t h a t  
dose-dependency  cannot  be  studied  only  with  the 
two-dose study presented to the authorities by Mon-
santo (11 and 33% of GMO in the diet). 
 e)  Since  anatomo-pathological  lesions  or  plas-
matic biochemical disruptions could arise long after 
t h e   b e g i n n i n g   o f   a   t r e a t m e n t ,   i t   i s   n o t   n e c e s s a r y   t o  
establish correlations between these statistical differ-
ences  and  histopathological  findings  (overall  within 
three months) to conclude on a disturbing sign, de-
spite what Monsanto et al are claiming. In addition, 
histological  slides  and  embedded  organs  are  the 
p r o p e r t y   o f   t h e   c o m p a n y ,   a n d   w e r e   n o t  
double-checked  by  official  committees  or  indepen-
dent authors. We ask for an official counter-analysis, 
i n   p a r t i c u l a r   o f   t h e   m a l e   k i d n e y s   i n   t h e s e   s t u d i e s ,   t h a t  
concentrate more than 43% of all disrupted parame-
t e r s   i n   a   m e t a -analysis of all published data on com-
mercialized GMOs [10]. 
 We  already  know  that  during  the  MON  863 
study,  Monsanto  highlighted  anatomic  signs  of 
“chronic progressive nephropathy” on GM-fed  male 
rats’ kidneys. However, Monsanto did not see these 
signs  as  being  noteworthy  due  to  the  fact  that,  ac-
c o r d i n g   t o   t h e m ,   t h e y   w e r e   w e l l   k n o w n   t o   o c c u r   i n   o l d  
Sprague-Dawley rats. This explanation was then pub-
l i c l y   r e p e a t e d   b y   t h e   p r e s i d e n t   o f   t h e   C G B ,   t h e   F r e n c h  
e v a l u a t i o n   c o m m i t t e e   f o r   t h e   G M O   i n   q u e s t i o n .   B u t  
these  rats  were  only  5  months  old,  and  still  quite 
young at the end of the experiment. Oddly enough, 
these anatomo-pathological signs on kidneys were not 
n o t i c e d   d u r i n g   t h e   s t u d i e s   o n   M O N   8 1 0   a n d   N K 6 0 3  
maize. Yet the rats were the same age and from the 
same strain.    
 f) The chemical composition of food/feed is an 
important  indication.  However  all  insecticide  tox-
ins/herbicide residues/unintended or unknown me-
tabolites (due for instance to insertional mutagenesis 
or new metabolites) are not assessed; thus the sub-
s t a n t i a l   e q u i v a l e n c e   w i t h   n o n   G M   p r o d u c t s   i s   n o t   a  
proof of innocuousness.  
 g) A bias for biological interpretations could also 
b e   s e e n   i n   t h e   f a c t   t h a t   t h e   r e g u l a t o r y   t o x i c o l o g i c a l  
tests were presented and commented for the authori-
ties  only  by  the  companies  developing  industrial 
products, and this has been the c a s e ,   f o r   a t   l e a s t   t h e  
last fifty years. Few studies have been conducted by 
independent groups such as Malatesta et al. [17-21] 
who found ultrastructural alterations of hepatic cells 
of mice that had eaten Roundup- tolerant GMOs. Fi-
n a m o r e ' s   s t u d y ,   w h i c h   f ocused  on  an  insecti-
cide-producing variety, suggested gut and peripheral 
i m m u n e   r e s p o n s e   t o   G M   c r o p   i n g e s t i o n   [ 2 2 ] .   N o   i n-
dustry-funded studies suggest potential side effects of 
G M O   c o n s u m p t i o n .   I t   i s   a   w e l l -known problem; for 
instance  in  the  bisphenol  A  controversy,  the  me-
ta-a n a l y s i s   o f   a l l   s t u d i e s   p e r f o r m e d   s h o w e d   t h a t   n o n e  
o f   t h e   i n d u s t r y -funded studies showed adverse effects 
of bisphenol A, whereas 90% of government funded 
ones showed hazards at various levels and various 
doses [23]. 
A  proposition  for  studies  conducted  indepen-
d e n t l y   f r o m   c o m p a n i e s   t o   t a c k l e   t h i s   i s s u e   h a s   b e e n  
m a d e   t o   t h e   C o u n c i l   o f   E u r o p e a n   M i n i s t e r s   b y   s o m e   o f  
us [24].  
Conclusions and perspectives 
 Controversy  on  biological  interpretations  is  a 
u s u a l   w a y   o f   a d v a n c e m e n t   i n   s c i e n c e .   I t   w ould how-
ever have been beneficial for the acceptance of bio-
technologies by the public at large, to close this scien-
tific debate by longer, more detailed, and transparent 
toxicological tests on GMOs, and in particular twenty 
years ago when the most widely gr o w n   G M O s   w e r e  
still experimental. 
 We wish to reassert that our work does not claim 
to  demonstrate  the  chronic  toxicity  of  the  GMOs  in 
q u e s t i o n ,   e s p e c i a l l y   s i n c e   i t   i s   b a s e d   o n   t h e   d a t a   o r i-
ginating from insufficient tests that were accepted by 
regulatory authorities and Monsanto et al., a fact for 
w h i c h   w e   a r e   n o t   i n   a n y   w a y   r e s p o n s i b l e .   F o r   t h e  
regulatory authorities, as well as Monsanto et al, these Int. J. Biol. Sci. 2010, 6 
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tests  prove  chronic  innocuousness  for  mammalian 
and  human  public  health.  And  they claim it is not 
essential  to  demonstrate  the  GMOs  innocuousness. 
This again raises the same issues and consequences. 
We have revealed the inefficiency both of these tests 
and of their statistical analysis and biological inter-
pretations,  for  the  various  reasons  detailed  above. 
Howe v e r ,   s o m e   o f   t h e   i n   v i v o   9 0 -d a y   t e s t s   a r e   n o t  
p e r f o r m e d   a n y   l o n g e r   t o d a y   t o   g e t   w o r l d w i d e   c o m-
mercial  authorizations,  especially  for  GMO  with 
“stacked events” (i.e. ,   p r o d u c i n g   o n e   o r   s e v e r a l   i n s e c-
ticides and tolerating one or two herbicides), and this 
is even more seriously inadequate since the so-called 
“cocktail effects” are not taken into consideration. 
The same controversy took place (February 2010) 
in India, in relation to the authorization process for a 
transgenic  eggplant  that  produces  a  new  Bt  insecti-
cide.  This  authorization  was  based  on  three-month 
t e s t s   o n   t h r e e   m a m m a l s   a n d   o t h e r   a n i m a l s   f o r   s h o r t e r  
times,  which  presented  significant  biological  effects 
after this GM consumption  [10,  25].   T h e   s a m e   a r g u-
ments were used in the debate in India. But in this 
case,  the  government  decided  to  take  the  time  to 
s t u d y   c h r o n i c   h e a l t h   e f f e c t s ,   f o l l o w i n g   o u r   e x p e r t i s e ,  
and therefore to implement a moratorium [26].  
 In   t h e   p r e s e n t   c a s e ,   w e   w i s h   t o   u n d e r l i n e   t h a t   t h e  
commercial GMOs in question contain pesticide re-
si d u e s ,   s o m e   o f   w h i c h   h a v e   b e e n   d e m o n s t r a t e d   a s  
human cellular endocrine disruptors at levels around 
1000 times below their presence in some GM feed [27]. 
Such Roundup residues are present in more than 80% 
of  edible  cultivated  GMOs.  Th i s   d o e s   n o t   e x c l u d e  
other possible effects. 
 As  a  conclusion,  we  call  for  the  promotion  of 
transparent,  independent  and  reproducible  health 
s t u d i e s   f o r   n e w   c o m m e r c i a l   p r o d u c t s ,   t h e   d i s s e m i n a-
t i o n   o f   w h i c h   i m p l i e s   c o n s e q u e n c e s   o n   a   l a r g e   s c a l e .  
Lifetime  studies  for  laboratory  animals  consuming 
G M O s   m u s t   b e   p e r f o r m e d ,   b y   c o n t r a s t   t o   w h a t   i s   d o n e  
t o d a y ,   l i k e   t h e   t w o -year long tests on rats for some 
p e s t i c i d e s   o r   s o m e   d r u g s .   S u c h   t e s t s   c o u l d   b e   a s s o-
ciated to transgenerational, reproductive or endocrine 
research studies. And moreover, shortcomings in ex-
perimental  designs  may  raise  major  questions  on 
other chemical authorizations. 
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